Design Therapeutics, Inc. (DSGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) today and set a price target of $5.00. The company’s shares opened today at $4.87.

CENTRE COUNTY, Pa (WJAC) — In Centre County, development is continuing along the Benner Pike, just outside of Bellefonte. It’s becoming one the county's top sites for new businesses.

Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). CARLSBAD, Calif., March 03, 2025 (GLOBE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: March 14 at 4:23:30 PM EDT Loading Chart for DSGN ...